SEOUL, Nov. 30 (Reuters) – The distribution arm of South Korean biotech company Celltrion (068270.KS) has signed supply agreements for its monoclonal antibody to treat COVID-19 with nine European countries, Celltrion Healthcare (091990.KQ) said Tuesday. .
Earlier this month, the European Commission approved the company’s antibody therapy Regkirona, which grants marketing authorization to adults with COVID-19 who are at increased risk of developing a serious condition.
The first batch of 50,000 doses will ship to Europe this year, and the company is in talks with 47 other countries, including Asia, Central and South America and the Middle East, Celltrion said in a statement.
The antibody treatment was initially approved in South Korea and has been administered to approximately 25,000 local COVID-19 patients since last week.
Laboratory-created monoclonal antibodies mimic natural antibodies in fighting infections. Unlike vaccines, they do not rely on the body to create an immune response and can therefore help individuals with weak or compromised immune systems.
Register now for FREE unlimited access to reuters.com
Reporting by Sangmi Cha; adaptation by Richard Pullin
Our Standards: The Thomson Reuters Trust Principles.